SVSÔNLINE

NEW ADVANCES AND DISCOVERIES IN VASCULAR SURGERY



Results from a prospective real-world multicentre clinical practice of CAS using the CGuard embolic prevention system: the IRONGUARD 2 study

PRESENTED BY:

Pasqualino Sirignano

Vascular and Endovascular Surgery Division Department of Surgery "Paride Stefanini" Policlinico Umberto I "Sapienza" University of Rome Chief Prof *Francesco Speziale*





IronGuard2 Study

131 (17.87%) symptomatic

Symptomatic

Aim: to evaluate periprocedural, 30-day, and 12-month outcomes in a prospective series of patients submitted to protected CAS with the **CGuard Embolic Prevention System** (EPS).



Methods: From January **2017** to June **2019** a physicianinitiated prospective multispecialty, multicentre study was initiated enrolling 733 consecutive patients admitted for protected CAS and treated using the CGuard EPS in 20 Italian centres.

600

500

400

300 200 100

0

Asymptomatic





Results





Results

		the variable N (%)	the variable N (%)	(OR; 95% CI)
Hypertension		0 (0)	4 (0.64)	1.00 (NA)
Diabetes		2 (0.43)	2 (0.75)	0.56 (1.75; 0.24-12.53
Dyslipidaemia		1 (0.55)	3 (0.54%)	0.98 (0.98; 0.10-9.51)
Smoking History		2 (0.65)	2 (0.46%)	0.72 (0.70; 0.09-5.04)
Coronary Artery Disease		3 (0.65)	1 (0.35%)	0.59 (1.83; 0.19-17.76
Octogenarians		3 (0.51)	1 (0.70)	0.76 (1.40; 0.14-13.58
High clinical risk		2 (0.59)	2 (0.50)	0.91 (1.11; 0.15-7.94)
Symptomatic Stenosis		1 (0.76)	3 (0.49)	0.70 (1.53; 0.15-14.88
Plaque	Hyperechoic	3 (0.52)	1 (0.61)	
	Isoechoic	3 (0.47)	1 (0.93)	
	Hypo-anechoic	3 (0.54)	1 (0.55)	
	Disomogeneous	4 (0.71)	0 (0)	0.47
	Ulcerated	3 (0.43)	1 (2.5)	(NA)
	Thin fibrous cap	4 (0.56)	0 (0)	
	Post-CEA restenosis	4 (0.57)	0 (0)	
	Unstable	3 (0.45)	1 (1.44)	0.28 (3.24; 0.33-31.58
Aortic Arch	Type I	2 (0.54)	2 (0.54)	
	Type II	2 (0.43)	2 (0.74)	1.00
	Type III	4 (0.57)	0 (0)	(NA)
	Bovine	4 (0.59)	0 (0)	
Tortuosity	None	3 (0.55)	1 (0.51)	
	Low	2 (0.45)	2 (0.69)	1.00
	Moderate	3 (0.55)	1 (0.52)	(NA)
	Severe	4 (0.59)	0 (0%)	
	Significant	3 (0.62)	1 (0.4)	0.70 (0.64; 0.06-6.20
Severe Calcification		2 (1.00)	2 (0.37)	0.30 (2.70; 0.37-19.30
Severe Thrombosis		3 (0.51)	1 (0.68)	0.80 (1.33; 0.13-12.88
Distal Protection		1 (0.71)	3 (0.50)	0.76 (0.70; 0.07-6.84
Predilatation		4 (0.70)	0 (0)	1.00 (NA)
Postdilatation		0 (0)	4 (0.65)	1.00 (NA)

At univariate analysis, none of the clinical, anatomical, or procedural characteristic was found to be statistically related to new stroke occurrence during the entire study period, including preoperative symptoms





Conclusions

 Results from the IRONGUARD-2 suggest that a widespread use of the CGuard-EPS mesh covered stents could guarantee an extremely low periprocedural adverse events rate

- Our data should be validated by a randomized trial, prospectively evaluating results with different stents' configuration





Thanks to everyone!!!

Policlinico Umberto I, Sapienza University of Rome Policlinico Sant'Andrea, Sapienza University of Rome Federico II Hospital, University of Naples Policlinico Le Scotte, University of Siena Annunziata Hospital, Cosenza Sant'Anna Hospital, Catanzaro Campus BioMedico University of Rome City Hospital, Mirano MultiMedica IRCCS Scientific Institute, Milan Sandro Pertini Hospital, Rome San Martino Hospital, University of Genua Galliera Hospital, Genua Mauriziano Umberto I Hospital, Turin S Carlo Poma Hospital, Mantova Tor Vergata University of Rome Città della Salute Hospital, Turin San Filippo Neri Hospital, Rome Moriggia Pelascini Hospital, Como Santa Maria Hospital, Udine San Camillo de Lellis Hospital, Rieti



SVSÔNLINE